바카라사이트 총판 승리바카라 targets 41 biosimilar launches by 2038, eyes U.S. Branchburg as CDMO hub

[by Ji, Yong Jun] At the 2026 JP Morgan Healthcare Conference, 바카라사이트 총판 승리바카라 presented its pipeline development roadmap encompassing novel drugs and next-generation biosimilars. The company also emphasized the competitive advantages of its Branchburg, New Jersey, manufacturing facility, acquired in 2025, and outlined its strategy to transform the site into a central hub for its global contract development and manufacturing organization (CDMO) operations.

Celltrion presented on January 13 (local time) its product pipeline development roadmap, covering new drugs and next-generation biosimilars, to global investors on the ‘Main Track,’ the main stage of the 2026 JP Morgan Healthcare Conference. During the presentation, the company also highlighted the competitive strengths of its U.S.-based manufacturing facility.

As the first speaker, Seo Jin-seok, Head of Business Division at Celltrion, stated, "Our company has entered a new phase of growth as a developer of novel drugs. Leveraging the stable cash flow generated by our biosimilar portfolio and the antibody technologies accumulated to date, we are actively expanding our new drug development initiatives."

Regarding the biosimilar business, Seo stated, "We aim to expand our current biosimilar portfolio from 11 products to a total of 41 by 2038. As a result, the targetable global market is expected to increase more than fourfold compared with last year, surpassing KRW 400 trillion (approximately USD 270.6 billion)." At present, Celltrion's biosimilar portfolio spans a broad range of therapeutic areas, including autoimmune disorders, oncology, bone diseases, and ophthalmic indications.

Seo subsequently presented a development roadmap encompassing 16 novel drug pipelines, including antibody-drug conjugates (ADCs), multispecific antibodies, neonatal Fc receptor (FcRn) inhibitors, and obesity therapeutics. Among these, the ADC candidates CT-P70 (development code), CT-P71, and CT-P73, along with the multispecific antibody candidate CT-P72, obtained Investigational New Drug (IND) approval last year and have advanced into Phase 1 clinical trials. Key clinical results from these four pipelines are expected to be disclosed sequentially beginning in the second half of this year.

In particular, CT-P70 recently received ‘Fast Track’ designation from the U.S. Food and Drug Administration (FDA), a development expected to further accelerate its clinical development. Celltrion also plans to seek Fast Track designation for additional core pipelines, including CT-P71, CT-P72, and CT-P73. In parallel, the company intends to submit IND applications for the new ADC candidate ‘CT-P74’ and the FcRn inhibitor ‘CT-P77’ in early 2027, with a cumulative total of 12 novel drug pipelines targeted for submission by 2028.

A development roadmap was also outlined for the next-generation obesity treatment candidate ‘CT-G32.’ Celltrion is advancing CT-G32 as a quadruple-acting agent, with its differentiation strategy centered on addressing interindividual variability in treatment efficacy and mitigating the potential side effect of muscle loss, two key limitations associated with existing obesity treatments. CT-G32 is progressing rapidly, with an IND submission targeted for H2 2027.

"We are accelerating new drug development through a combination of in-house R&D capabilities and collaborations with global biotechnology companies. These efforts are expected to further reinforce Celltrion's position as a new drug development company," Seo emphasized.

Following this, Lee Hyuk-jae, Senior Executive Vice President of 바카라사이트 총판 승리바카라, outlined plans to expand investment in the Branchburg, U.S., manufacturing facility acquired last year. The company explained that securing a local production base in the U.S. has mitigated tariff-related risks and reinforced global supply chain stability in response to its expanding product portfolio and increasing production demand. The facility is expected to begin generating revenue as a contract manufacturing organization (CMO) starting this year.

바카라사이트 총판 승리바카라 plans to first implement a phased capacity expansion strategy, increasing its drug substance (DS) manufacturing capacity from the current 66,000 liters to 99,000 liters by 2028. An additional expansion of 33,000 liters is planned by 2030, bringing total capacity to 132,000 liters. In addition, the company intends to establish a finished drug product (DP) manufacturing facility, thereby completing an integrated, end-to-end supply chain in the United States.

Celltrion plans to position its Branchburg facility as the cornerstone of a future U.S.-based research center and a central hub for its global integrated CDMO operations. Through this strategy, the company aims to further strengthen its global market leadership by establishing a ‘dual axis’ structure, linking its Songdo headquarters in Korea with its U.S. manufacturing base, while maximizing synergy with local research centers.

"We intend to position the U.S. manufacturing site as a 'core production hub' that generates revenue not only by supplying Celltrion's products to the North American market but also by providing contract manufacturing services for global pharmaceutical companies. Through this approach, we will simultaneously enhance the stability and operational efficiency of the global supply chain. Following the establishment of production facilities, we will also pursue the creation of a global R&D center in collaboration with a local bio cluster, with the objective of attracting top-tier talent and further strengthening our development competitiveness," Lee said.